Upload

Loading icon Loading...

This video is unavailable.

GRACEcast-110_Lung-Cancer_ASCO 2012 LC Highlights: Dr. Socinski on Single Agent vs Doublet Chemo

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to like GRACE - Global Resource for Advancing Cancer Education's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to dislike GRACE - Global Resource for Advancing Cancer Education's video.

Sign in to YouTube

Sign in with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to add GRACE - Global Resource for Advancing Cancer Education's video to your playlist.

Published on Aug 19, 2012

http://cancerGRACE.org/

Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

Loading icon Loading...

Loading icon Loading...

Loading icon Loading...

The interactive transcript could not be loaded.

Loading icon Loading...

Loading icon Loading...

Ratings have been disabled for this video.
Rating is available when the video has been rented.
This feature is not available right now. Please try again later.

Loading icon Loading...

Loading...
Working...
to add this to Watch Later

Add to